Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Over 200 delegates travelled from more than 50 countries to attend the first ever conference on Medicine Quality and Public Health (MQPH 2018) in Oxford from 23-28 Sept. The conference, at Keble College, brought together experts in pharmacy, public health, chemistry, law, sociology, governance and ethics, from medicines regulatory authorities, academia, pharmaceutical industry, NGOs, and international organisations.

MQPH discussion panel, with Celine Caillet, Serena Vickers, Muhammad Zaman, Richard Jahnke

The many conference partners included the US Pharmacopeia (USP), WHO, Wellcome and the Concept Foundation. The latest evidence on the prevention, detection and response to substandard, falsified and unregulated medicines was discussed along with inspiring collaborations and strategies to tackle this global challenge.

Opening speakers Dr Suzanne Hill, Director of the Essential Medicines and Health Products Department of the World Health Organization (WHO), Prof Louise Richardson, Vice-Chancellor of the University of Oxford, Ms Agnes Sitta Kijo, Acting Director General of the Tanzanian Food and Drugs Authority (TFDA), and Prof Sir Nicholas White, Chairman of the MORU Tropical Health Network, called for collaborative efforts beyond geographic borders and sectoral divisions to more urgently intervene to address the serious public health problem of substandard and falsified medical products.

A brief Oxford Statement, under the auspices of the conference and the Let's Demand Medicines We Can Trust campaign, was released 14 Nov 2018. Prof Paul Newton, LOMWRU Director and Head of the IDDO Medicine Quality Group explained: “The conference consensus statement outlines the key opportunities and priority ‘next steps’ to tackle poor quality medicines. We hope to organize many more opportunities to collaborate and make a real difference to the lives of those affected by this unacceptable global health challenge.”

The full story is available on the Oxford Tropical Medicine website

Similar stories

Study finds almost two-thirds of patients are systematically excluded from drug trials

A new WWARN study has found that nearly two-thirds of the malaria-positive patients who present to health facilities are systematically excluded from “classical” anti-malarial treatment efficacy trials.

New antibiotic combination speeds recovery from severe scrub typhus, which infects 1 million people per year

Treating patients ill with severe scrub typhus – a life-threatening infection that kills tens of thousands of people a year - with a combination of intravenous antibiotics doxycycline and azithromycin is significantly more effective than the current monotherapy of using either drug alone, say researchers in a study published in the New England Journal of Medicine (NEJM).

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Study supports evidence ivermectin not effective to treat COVID-19

21 Feb 2023 Oxford UK - High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.

Shobhana Nagraj, Women in Science

Clinical Researcher Shobhana Nagraj, from the Health Systems Collaboratives in Oxford, tells us about the female role models who inspired her to follow her dreams

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.